Bind and Amgen complete research program

|By:, SA News Editor

Citing results that were not compelling enough to proceed, Bind Therapeutics (BIND -3.4%) and Amgen (AMGN +0.6%) notify each other that they will not be exercising their options to develop an Accurin incorporating the Amgen therapeutic payload. 

The collaboration began in January 2013 with the goal of developing a nanomedicine for treating solid cancer tumors based on Bind's platform for targeted and programmable nanomedicines and Amgen's undisclosed proprietary cancer compound. 

Bind CEO Scott Minick says that his company will proceed undeterred with its collaborations with AstraZeneca (AZN +2%), Roche (RHHBY -0.6%) and Pfizer (PFE +1%).